Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jamal, O. S
Right arrow Articles by Scott, K. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jamal, O. S
Right arrow Articles by Scott, K. F
Ann Rheum Dis 1998;57:550-558 ( September )

Extended reports

Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium Omar S Jamal,a Philip G Conaghan,a Anne M Cunningham,b Peter M Brooks,a Vincent F Munro,c Kieran F Scotta

a The Arthritis Research Institute, Department of Medicine, The University of New South Wales, Australia, b The Garvan Institute of Medical Research, c and Department of Anatomical Pathology, St Vincent's Hospital, Sydney, Australia

Correspondence to: Dr K Scott, Department of Medicine, The University of New South Wales, St Vincent's Hospital, Level 9, Garvan Institute Building, 384 Victoria Street, Darlinghurst NSW 2010, Australia.

Accepted for publication 8 July 1998

OBJECTIVE---To determine the localisation and level of expression of human type IIa secretory phospholipase A2 (sPLA2) in the synovium of rheumatoid arthritis (RA), osteoarthritis (OA), and non-arthritic (NA) patients and to examine the relation between sPLA2 and histological features of inflammation.
METHODS---Immunoperoxidase staining using the anti-sPLA2 monoclonal antibody 9C1 was performed on frozen sections of knee synovium of 10 RA, 10 OA, and 10 NA patients. sPLA2 positive cells were scored on a scale of 0-3 in 10 fields of a representative tissue section from each case. Double labelling imunofluorescence confocal microscopy with antibodies to CD14 or CD45 and 9C1 was used to determine cell type specificity. Inflammation was assessed by semiquantitative scoring of lining layer thickness and mononuclear cell infiltrates (MC) and a cumulative inflammation score, generated by summing the two parameters. Scores in each group were compared using non-parametric statistical analysis.
RESULTS---sPLA2 was localised to endothelium (EC), vascular smooth muscle (VSM), and mast cells (M) in all tissue sections. In RA and OA sections, staining was seen in both macrophage-like and fibroblast-like cells in the synovial lining layer (LL) and subsynovial lining layer (SLL). Perineural cells stained positively. Subintimal lymphoid aggregates (LA) were negative in all sections. The RA group showed significantly greater staining in extravascular synovial tissue (median 3.6, range 1.5-6.0) than the OA (median 1.95, range 0-5.3) or NA (median 0, range 0-5.9) groups (p<0.05). LL staining was significantly higher in RA than both OA and NA sections (p<0.05). The OA group showed a trend to higher staining scores than the NA group that did not reach significance. There was a significant correlation between the sPLA2 staining score and inflammation score within the RA patient group (p<0.05).
CONCLUSIONS---The synovium is a site of increased expression of sPLA2 antigen in both RA and OA relative to NA. Its presence in both fibroblast and macrophage-like cells in the LL and SLL of synovial tissue in RA and OA, but not NA, indicates that the enzyme is specifically induced in these regions in both conditions with expression in the LL being particularly characteristic of RA. The widespread expression of sPLA2 in synovium suggests it is likely to play a significant part in synovial pathology

Keywords: synovium; phospholipase A2; immunohistochemistry; confocal microscopy

© 1998 by Annals of the Rheumatic Diseases


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
T. Ookoshi, K. Hasegawa, Y. Ohhashi, H. Kimura, N. Takahashi, H. Yoshida, R. Miyazaki, Y. Goto, and H. Naiki
Lysophospholipids induce the nucleation and extension of {beta}2-microglobulin-related amyloid fibrils at a neutral pH
Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3247 - 3255.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Levick, D. Loch, B. Rolfe, R. C. Reid, D. P. Fairlie, S. M. Taylor, and L. Brown
Antifibrotic Activity of an Inhibitor of Group IIA Secretory Phospholipase A2 in Young Spontaneously Hypertensive Rats.
J. Immunol., June 1, 2006; 176(11): 7000 - 7007.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Moghaddami, M. Costabile, P. K. Grover, H. P. A. Jersmann, Z. H. Huang, C. S. T. Hii, and A. Ferrante
Unique Effect of Arachidonic Acid on Human Neutrophil TNF Receptor Expression: Up-Regulation Involving Protein Kinase C, Extracellular Signal-Regulated Kinase, and Phospholipase A2
J. Immunol., September 1, 2003; 171(5): 2616 - 2624.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Hegen, L. Sun, N. Uozumi, K. Kume, M. E. Goad, C. L. Nickerson-Nutter, T. Shimizu, and J. D. Clark
Cytosolic Phospholipase A2{alpha}-deficient Mice Are Resistant to Collagen-induced Arthritis
J. Exp. Med., May 19, 2003; 197(10): 1297 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D.-W. Park, J.-R. Kim, S.-Y. Kim, J.-K. Sonn, O.-S. Bang, S.-S. Kang, J.-H. Kim, and S.-H. Baek
Akt as a Mediator of Secretory Phospholipase A2 Receptor-Involved Inducible Nitric Oxide Synthase Expression
J. Immunol., February 15, 2003; 170(4): 2093 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Chandra, J. Jasti, P. Kaur, S. Dey, M. Perbandt, A. Srinivasan, Ch. Betzel, and T. P. Singh
Crystal Structure of a Complex Formed between a Snake Venom Phospholipase A2 and a Potent Peptide Inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 A Resolution
J. Biol. Chem., October 18, 2002; 277(43): 41079 - 41085.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Murakami, K. Yoshihara, S. Shimbara, G. Lambeau, M. H. Gelb, A. G. Singer, M. Sawada, N. Inagaki, H. Nagai, M. Ishihara, et al.
Cellular Arachidonate-releasing Function and Inflammation-associated Expression of Group IIF Secretory Phospholipase A2
J. Biol. Chem., May 17, 2002; 277(21): 19145 - 19155.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Nijmeijer, W. K Lagrand, A. Baidoshvili, Y. T.P Lubbers, W. T. Hermens, C. J.L.M Meijer, C. A Visser, C.E. Hack, and H. W.M Niessen
Secretory type II phospholipase A2 binds to ischemic myocardium during myocardial infarction in humans
Cardiovasc Res, January 1, 2002; 53(1): 138 - 146.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Bidgood, O. S. Jamal, A. M. Cunningham, P. M. Brooks, and K. F. Scott
Type IIA Secretory Phospholipase A2 Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes
J. Immunol., September 1, 2000; 165(5): 2790 - 2797.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. B. Church, A. S. Inglis, A. Tseng, R. Duell, P.-W. Lei, K. J. Bryant, and K. F. Scott
A Novel Approach to the Design of Inhibitors of Human Secreted Phospholipase A2 Based on Native Peptide Inhibition
J. Biol. Chem., August 24, 2001; 276(35): 33156 - 33164.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 BMJ Publishing Group Ltd & European League Against Rheumatism